Research, Medical devices, Genetics, Other Health, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Politics of the European Union, Foreign relations of the European Union, European Union, DNA sequencing, Grail, Illumina, Inc., Competition law, Illumina, European Economic Area, European Union merger law
Thursday, July 22, 2021 - 5:49pm
We look forward to presenting our position during the Phase II process, said Charles Dadswell, General Counsel for Illumina.
- We look forward to presenting our position during the Phase II process, said Charles Dadswell, General Counsel for Illumina.
- Illumina is also challenging the ECs jurisdiction to investigate the transaction under Article 22 of the European Union (EU) Merger Regulation.
- Illumina has filed an action in the General Court of the EU seeking annulment of the ECs jurisdiction to review the acquisition.
- Illuminas re-acquisition of GRAIL means that millions of citizens across the European Economic Area (EEA) will be able to access life-saving early cancer screening years sooner.